|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Interventional treatment for unresectable hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC) is the sixth most common cancer and third leading cause of cancer-related death in the world. The Barcelona clinic liver cancer classification is the current standard classification system for the clinical management of patients with HCC and suggests that patients with intermediate-stage HCC benefit from transcatheter arterial chemoembolization(TACE). Interventional treatments such as TACE, balloon-occluded TACE, drug-eluting bead embolization, radioembolization, and combined therapies including TACE and radiofrequency ablation, continue to evolve, resulting in improved patient prognosis. However, patients with advanced-stage HCC typically receive only chemotherapy with sorafenib, a multi-kinase inhibitor, or palliative and conservative therapy. Most patients receive palliative or conservative therapy only, and approximately 50% of patients with HCC are candidatesfor systemic therapy. However, these patients require therapy that is more effective than sorafenib or conservative treatment. Several researchers try to perform more effective therapies, such as combined therapies(TACE with radiotherapy and sorafenib with TACE), modified TACE for HCC with arterioportal or arteriohepatic vein shunts, TACE based on hepatic hemodynamics, and isolated hepatic perfusion. This review summarizes the published data and data on important ongoing studies concerning interventional treatments for unresectable HCC and discusses the technical improvements in these interventions, particularly for advanced-stage HCC. | Satoru Murata Takahiko Mine Fumie Sugihara Daisuke Yasui Hidenori Yamaguchi Tatsuo Ueda Shiro Onozawa Shin-ichiro Kumita | 2014 | World Journal of Gastroenterology2014，20，37： | 38 |
| 2 | Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease显示文摘AIM: To evaluate the clinical utility of serum fibrosis markers,including YKL-40, in patients with HCV-associated liver disease.METHODS: A total of 109 patients with HCV-associated liver disease were enrolled. We measured serum type Ⅳ collagen, amino-terminal peptide of type Ⅲ procollagen (PⅢP),hyaluronic acid (HA), YKL-40 levels and biochemical.Parameters by RIA or ELISA. Eighty-eight patients underwent liver biopsy, and 67 of 109 patients received interferon (IFN)therapy. We also investigated the relationship between the concentrations of serum fibrosis markers and histological fibrosis scores (METAVIR), and evaluated the changes of the levels of fibrosis markers before and after the IFN therapy.RESULTS: The increase in serum levels of all markers,particularly HA, was correlated with the progression of liver fibrosis (for type Ⅳ collagen, F= 9.076, P<0.0001; for PⅢP,F= 9.636, P<0.0001; for HA, F= 13.128, P<0.0001; and for YKL-40, F= 8.016, P<0.0001). YKL-40 had strong correlation with HA (r= 0.536, P<0.0001). Based on the receiver operating curve (ROC), the ability of serum HA exceeded the abilities of other serum markers to determine fibrosis score 4 from fibrosis score 0-3 (AUC = 0.854). While YKL-40 was superior to other fibrosis markers for predicting severe fibrosis (F2-F4) from mild fibrosis (F0-F1) (YKL-40, AUC = 0.809;HA, AUC = 0.805). After IFN therapy, only YKL-40 values significantly decreased not only in the responder group,but also in the nonresponder group (P = 0.03).CONCLUSION: YKL-40 may be a useful non-invasive serum marker to estimate the degree of liver fibrosis and to evaluate the efficacy of IFN therapies in patients with HCV-associated liver disease. | Yukiko Saitou Katsuya Shiraki Yutaka Yamanaka Yumi Yamaguchi Tomoyuki Kawakita Norihiko Yamamoto Kazushi Sugimoto Kazumoto Murata Takeshi Nakano | 2005 | World Journal of Gastroenterology2005，11，4： | 21 |
| 3 | Diagnostic and therapeutic single-operator cholangiopancreatoscopy in biliopancreatic diseases:Prospective multicenter study in Japan显示文摘AIM: To assess the utility and safety of single-operator cholangiopancreatoscopy(SOCPS) using the Spy Glass system in widespread clinical application for biliary and pancreatic diseases.METHODS: This study was a prospective case series conducted in 20 referral centers in Japan. There were 148 patients who underwent SOCPS; 124 for biliary diseases and 24 for pancreatic diseases. The attempted interventions were SOCPS examination, SOCPS-directed tissue sampling, and therapy for stone removal, among others. The main outcomes were related to the procedure success rate in terms of visualizing the target lesions, SOCPS-directed adequate tissue sampling, and complete stone removal. RESULTS: A total of 148 patients were enrolled for the diagnosis of indeterminate biliary and pancreatic lesions or treatment of biliary and pancreatic disease. The overall procedure success rate of visualizing the target lesions was 91.2%(135/148). The overall procedural success rates of visualizing the target lesions of diagnostic SOCPS in the bile duct and pancreatic duct were 95.5%(84/89) and 88.2%(15/17), respectively. Diagnosis: the overall adequate tissue for histologic examination was secured in 81.4% of the 86 patients who underwent biopsy under SOCPS(bile duct, 60/75, 80.0%; pancreatic duct, 10/11, 90.9%). The accuracy of histologic diagnosis using SOCPS-directed biopsies in indeterminate bile duct lesions was 70.7%(53/75). In the pancreatic duct, the accuracy of SOCPS visual impression of intraductal papillary mucinous neoplasm was 87.5%(14/16). Stone therapy: complete biliary and pancreatic stone clearance combined with SOCPS-directed stone therapy using electrohydraulic lithotripsy or laser lithotripsy was achieved in 74.2%(23/31) and 42.9%(3/7) of the patients, respectively. Others: SOCPS using the Spy Glass system was used in cannulation of the cystic duct in two patients and for passing across the obstructed self-expandable metallic stent for a malignant biliary stricture in two patients. All procedures were successful in both SOCPS-guided therapies. The incidence of procedure-related adverse events was 5.4%(8/148). CONCLUSION: SOCPS with direct visualization and biopsy for diagnosis and SOCPS-directed therapy for biliary and pancreatic diseases can be safely performed with a high success rate. | Toshio Kurihara Ichiro Yasuda Hiroyuki Isayama Toshio Tsuyuguchi Taketo Yamaguchi Ken Kawabe Yoshinobu Okabe Keiji Hanada Tsuyoshi Hayashi Takao Ohtsuka Syuhei Oana Hiroshi Kawakami Yoshinori Igarashi Kazuya Matsumoto Kiichi Tamada Shomei Ryozawa Hiroki Kawashima Yutaka Okamoto Iruru Maetani Hiroyuki Inoue Takao Itoi | 2016 | World Journal of Gastroenterology2016，22，5： | 20 |
| 4 | Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy显示文摘AIM: To investigate the effect of probiotic bacterium,Clostridium butyricum MIYAIRI 588 strain (CBM) on the changes of the fecal flora in Helicobacter pylori(H pylori)treatment.METHODS: Thirty-five patients with gastric or duodenal ulcers positive for Hpylori were randomized either to 1 wk amoxicillin, clarithromycin, lansoprazole (Group 1) or to the same regimen supplemented with CBM 7 dahead of the triple therapy (Group 2). Stool samples were collected before and 2, 4, 7, 15, and 22 d after the starting eradication therapy, and were examined intestinal flora. Patients were required to keep a diary record of their condition. RESULTS: Obligate anaerobes decreased significantly on d 2, 4, 8 and 15 in Group 1. On the other hand, they did not decrease significantly in Group 2. The Escherichiacoli was dominant bacterium in Enterobacteriaceae, butthat was replaced by other species such as Klebsiella and Enterobacter after eradication in Group 1. The change was suppressed in Group 2. Abdominal symptoms were less frequent in Group 2 than in Group 1.CONCLUSION: The combined use of CBM reduced the changes in the intestinal flora and decreased the incidence of gastrointestinal side effects. | Izumi Shimbo Taketo Yamaguchi Takeo Odaka Kenichi Nakajima Akinori Koide Hidehiko Koyama Hiromitsu Saisho | 2005 | World Journal of Gastroenterology2005，11，47： | 18 |
| 5 | Prenatal diagnosis of methylmalonic aciduria by analysis of organic acids and total homocysteine in amniotic fluid显示文摘背景:Methylmalonic 酸尿(MMA ) 是在中国的器官的酸尿的最经常的疾病。各种各样的生物化学的策略为 MMA 的出生前的诊断被跟随。然而,后来, MMA 影响的胎儿减少了 methylmalonic 酸的排泄,出生前的生物化学的诊断的困难是明显的。煤气的层析团分光术(GC/MS ) 和双人脚踏车团分光术(ESI/MS/MS ) 允许我们在影响胎儿识别疾病。这研究的目的是在 MMA 的出生前的诊断在羊膜的液体决定有机酸和全部的人半胱氨酸的分析的价值。方法:临床诊断并且有 MMA 的九个职业人员乐队的结果并且出生前在风险基于九个胎儿的生物化学的分析诊断因为 MMA 被调查。从在为 MMA 的风险的怀孕和新陈代谢的联盟者正常怀孕的羊膜的液体样品在 16 点被获得 - 24 星期怀孕期。Methylmalonic 酸和甲基枸橼酸被 GC/MS 测量, propionylcarnitine 被 ESI/MS/MS 分析,并且全部的人半胱氨酸由荧光极化免疫分析是坚定的。结果:在二怀孕, methylmalonic 酸的高水平,甲基枸橼酸, propionylcarnitine,和总数,人半胱氨酸在胎儿显示了联合 MMA 和 homocysteinemia。继续的怀孕和收到的维生素 B12 作为出生前的处理,和其它补充的母亲之一终止了她的怀孕。在一个,怀孕, methylmalonic 酸的显著地提高的层次,甲基枸橼酸,和 propionylcarnitine,和正常全部的人半胱氨酸铺平被发现在胎儿显示孤立的 MMA;流产在这个案例上被执行。在另外的六怀孕,上述提及的代谢物的所有层次是正常的建议胎儿没被 MMA 影响。diagnoses 被严峻的尿有机酸和血浆总数人半胱氨酸在交货以后证实。结论:MMA 的新陈代谢的畸形在怀孕期早发生。在羊膜的液体的全部的人半胱氨酸的水平可以是胎儿的联合 MMA 和 homocysteinemia 的另外的指示物。在羊膜的液体的全部的人半胱氨酸水平的决心可以为疾病的出生前的诊断成为一个方便、可靠的方法。 | ZHANG Yao YANG Yan-ling HASEGAWA Yuki YAMAGUCHI Seiji SHI Chun-yan SONG Jin-qing SAYAMI Sujan LIU Ping YAN Rong DONG Jin-hua QIN Jiong | 2008 | Chinese Medical Journal2008，，3： | 18 |
| 6 | Intraductal neoplasm of the intrahepatic bile duct: Clinicopathological study of 24 cases显示文摘AIM: To investigate the clinicopathological features of intraductal neoplasm of the intrahepatic bile duct (INihB). METHODS: Clinicopathological features of 24 cases of INihB, which were previously diagnosed as biliary papillomatosis or intraductal growth of intrahepatic biliary neoplasm, were reviewed. Mucin immunohistochemistry was performed for mucin (MUC)1, MUC2, MUC5AC and MUC6. Ki-67, P53 and β-catenin immunoreactivity were also examined. We categorized each tumor as adenoma (low grade), borderline (intermediate grade), and malignant (carcinoma in situ , high grade including tumors with microinvasion). RESULTS: Among 24 cases of INihB, we identified 24 tumors. Twenty of 24 tumors (83%) were composed of a papillary structure; the same feature observed in intraductal papillary neoplasm of the bile duct (IPNB). In contrast, the remaining four tumors (17%) showed both tubular and papillary structures. In three of the four tumors (75%), macroscopic mucin secretion was limited but microscopic intracellular mucin was evident. Histologically, 16 tumors (67%) were malignant, three (12%) were borderline, and five (21%) were adenoma. Microinvasion was found in four cases (17%). Immunohistochemical analysis revealed that MUC1 was not expressed in the borderline/adenoma group but was expressed only in malignant lesions (P = 0.0095). Ki-67 labeling index (LI) was significantly higher in the malignant group than in the borderline/adenoma group (22.2 ± 15.5 vs 7.5 ± 6.3, P < 0.01). In the 16 malignant cases, expression of MUC5AC showed borderline significant association with high Ki-67 LI (P = 0.0622). Nuclear expression of β-catenin was observed in two (8%) of the 24 tumors, and these two tumors also showed MUC1 expression. P53 was negative in all tumors. CONCLUSION: Some cases of INihB have a tubular structure, and are subcategorized as IPNB with tubular structure. MUC1 expression in INihB correlates positively with degree of malignancy. | Yoshiki Naito Hironori Kusano Osamu Nakashima Eiji Sadashima Satoshi Hattori Tomoki Taira Akihiko Kawahara Yoshinobu Okabe Kazuhide Shimamatsu Jun Taguchi Seiya Momosaki Koji Irie Rin Yamaguchi Hiroshi Yokomizo Michiko Nagamine Seiji Fukuda Shinichi Sugiyama Naoyo Nishida Koichi Higaki Munehiro Yoshitomi Masafumi Yasunaga Koji Okuda Hisafumi Kinoshita Masayoshi Kage Masamichi Nakayama Makiko Yasumoto Jun Akiba Hirohisa Yano | 2012 | World Journal of Gastroenterology2012，18，28： | 16 |
| 7 | Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer显示文摘AIM: To investigate the prognostic role of KRAS and BRAF mutations after adjustment for microsatellite instability(MSI) status in Japanese colorectal cancer(CRC) population.METHODS: We assessed KRAS and BRAF mutations and MSI status in 813 Japanese patients with curatively resected, stage Ⅰ-Ⅲ CRC and examined associations of these mutations with disease-free survival(DFS) and overall survival(OS) using uni- and multivariate Cox proportional hazards models.RESULTS: KRAS and BRAF mutations were detected in 312(38%) of 812 and 40(5%) of 811 tumors, respectively. KRAS mutations occurred more frequently in females than in males(P = 0.02), while the presence of BRAF mutations was significantly associated with the female gender(P = 0.006), proximal tumor location(P < 0.001), mucinous or poorly differentiated histology(P < 0.001), and MSI-high tumors(P < 0.001). After adjusting for relevant variables, including MSI status, KRAS mutations were associated with poorer DFS(HR = 1.35; 95%CI: 1.03-1.75) and OS(HR = 1.46; 95%CI: 1.09-1.97). BRAF mutations were poor prognostic factors for DFS(HR = 2.20; 95%CI: 1.19-4.06) and OS(HR = 2.30; 95%CI: 1.15-4.71). Neither the BRAF by MSI interaction test nor the KRAS by MSI interaction test yielded statistically significant results for DFS and OS.CONCLUSION: KRAS and BRAF mutations are associated with inferior survival, independent of MSI status, inJapanese patients with curatively resected CRC. | Shigenori Kadowaki Miho Kakuta Shuhei Takahashi Akemi Takahashi Yoshiko Arai Yoji Nishimura Toshimasa Yatsuoka Akira Ooki Kensei Yamaguchi Keitaro Matsuo Kei Muro Kiwamu Akagi | 2015 | World Journal of Gastroenterology2015，21，4： | 14 |
| 8 | Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization显示文摘AIM: To detect the expression of a proliferation-related ligand on human hepatocellular carcinoma (HCC) cell lines (SK-Hep1, HLE and HepG2) and in culture medium.METHODS: APRIL expression was analyzed by Western blotting in HCC cell lines. Effects of APRIL to cell count and angiogenesis were analyzed, too.RESULTS: Recombinant human APRIL (rhAPRIL) increased cell viability of HepG2 cells and, in HUVEC, rhAPRIL provided slight tolerance to cell death from serum starvation. Soluble APRIL (sAPRIL) from HLE cells increased after serum starvation, but did not change in SK-Hep1 or HepG2 cells. These cells showed down-regulation of VEGF after incubation with anti-APRIL antibody.Furthermore, culture medium from the HCC cells treated with anti-APRIL antibody treatment inhibited tube formation of HUVECs.CONCLUSION: Functional expression of APRIL might contribute to neovascularization via an upregulation of VEGF in HCC. | Hiroshi Okano Katsuya Shiraki Yutaka Yamanaka Hidekazu Inoue Tomoyuki Kawakita Yukiko Saitou Yumi Yamaguchi Naoyuki Enokimura Keiichi Ito Norihiko Yamamoto Kazushi Sugimoto Kazumoto Murata Takeshi Nakano | 2005 | World Journal of Gastroenterology2005，11，30： | 13 |
| 9 | International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas显示文摘 | Masao Tanaka Carlos Fernández-del Castillo Volkan Adsay Suresh Chari Massimo Falconi Jin-Young Jang Wataru Kimura Philippe Levy Martha Bishop Pitman C. Max Schmidt Michio Shimizu Christopher L. Wolfgang Koji Yamaguchi Kenji Yamao | 2012 | Pancreatology2012，，3： | 13 |
| 10 | Novel serum tumor marker, RCASl, in pancreatic diseases显示文摘AIM: As tumor markers for pancreatic carcinoma,carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma.METHODS: A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers,CEA (highly specific for pancreatic cancer) and CA 19-9 (highly sensitive for pancreatic cancer), in 48 patients with pancreatic exocrine tumors.RESULTS: When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone (55%) was higher than that of CEA alone (27%) and the specificity of RCAS1 alone (92%) was greater than that of CA19-9 alone (78%). When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 (95%) was superior to those of CA19-9 alone (78%), RCAS1 alone (55%, P = 0.002),CEA alone (27%) (P<0.001), RCAS1 and CEA (59%) and CA19-9 and CEA (82%).CONCLUSION: These results suggest that the combination of RCASL and CA19-9 is highly sensitive for pancreatic carcinoma. | Koji Yamaguchi Munechika Enjoji Manabu Nakashima Makoto Nakamuta Takashi Watanabe Masao Tanaka | 2005 | World Journal of Gastroenterology2005，11，33： | 12 |
| 11 | Prevention of esophageal strictures after endoscopic submucosal dissection显示文摘Endoscopic mucosal resection(EMR) and endoscopic submucosal dissection(ESD) have recently been accepted as less invasive methods for treating patients with early esophageal cancers such as squamous cell carcinoma and dysplasia of Barrett's esophagus.However,the large defects in the esophageal mucosa often cause severe esophageal strictures,which dramatically reduce the patient's quality of life.Although preventive endoscopic balloon dilatation can reduce dysphagia and the frequency of dilatation,other approaches are necessary to prevent esophageal strictures after ESD.This review describes several strategies for preventing esophageal strictures after ESD,with a particular focus on anti-inflammatory and tissue engineering approaches.The local injection of triamcinolone acetonide and other systemic steroid therapies are frequently used to prevent esophageal strictures after ESD.Tissue engineering approaches for preventing esophageal strictures have recently been applied in basic research studies.Scaffolds with temporary stents have been applied in five cases,and this technique has been shown to be safe and is anticipated to prevent esophageal strictures.Fabricated autologous oral mucosal epithelial cell sheets to cover the defective mucosa similarly to how commercially available skin products fabricated from epidermal cells are used for skin defects or in cases of intractable ulcers.Fabricated autologous oralmucosal-epithelial cell sheets have already been shown to be safe. | Shinichiro Kobayashi Nobuo Kanai Takeshi Ohki Ryo Takagi Naoyuki Yamaguchi Hajime Isomoto Yoshiyuki Kasai Takahiro Hosoi Kazuhiko Nakao Susumu Eguchi Masakazu Yamamoto Masayuki Yamato Teruo Okano | 2014 | World Journal of Gastroenterology2014，20，41： | 12 |
| 12 | Xanthogranulomatous cholecystitis mimicking gallbladder carcinoma with a false-positive result on fluorodeoxyglucose PET显示文摘Recently, several reports have demonstrated that fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in differentiating between benign and malignant lesions in the gallbladder. However, there is a limitation in the ability of FDG-PET to differentiate between inflammatory and malignant lesions. We herein present a case of xanthogranulomatous cholecystitis misdiagnosed as gallbladder carcinoma by ultrasonography and computed tomography. FDG-PET also showed increased activity. In this case, FDG-PET findings resulted in a false-positive for the diagnosis of gallbladder carcinoma.Recently, several reports have demonstrated that fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in differentiating between benign and malignant lesions in the gallbladder. However, there is a limitation in the ability of FDG-PET to differentiate between inflammatory and malignant lesions. We herein present a case of xanthogranulomatous cholecystitis misdiagnosed as gallbladder carcinoma by ultrasonography and computed tomography. FDG-PET also showed increased activity. In this case, FDG-PET findings resulted in a false-positive for the diagnosis of gallbladder carcinoma. | Isamu Makino Takahiro Yamaguchi Nariatsu Sato Toshiaki Yasui Ichiro Kita | 2009 | World Journal of Gastroenterology2009，15，29： | 11 |
| 13 | 蛋白酶激活受体2在载脂蛋白E缺陷小鼠的血管炎症和动脉粥样硬化中发挥关键作用显示文摘凝血系统与血管炎症密切相关,尽管其潜在机制仍不清楚。最近的研究结果表明,蛋白酶激活受体(protease-activated receptor,PAR)2——活化因子X(activated factor X,FXa)的主要受体之一——在血管细胞和白细胞中均有表达,这提示PAR-2可能参与炎症性疾病的发病机制。 | Hara T Phuong PT Fukuda D Yamaguchi K Murata C Nishimoto S Yagi S Kusunose K Yamada H Soeki T Wakatsuki T Imoto I Shimabukuro M Sata M 刘青 叶鹏 | 2018 | 中华高血压杂志2018，26，6： | 11 |
| 14 | Dynamics of 5-methylcytosine and 5-hydroxymethylcytosine during germ cell reprogramming显示文摘以前的研究揭示了初发的细菌房间(PGC ) 经历的那只老鼠为 totipotency 重设 epigenome 的染色体宽的 DNA methylation reprogramming。然而,有 5-hydroxymethylcytosine (5hmC ) 的产生的精确 5-methylcytosine (5mC ) 动力学和它的关系不是清楚的。这里,我们在 PGC reprograming 和细菌房间开发期间分析了 5mC 和 5hmC 的动力学。出人意料地,我们在 5mC 和 5hmC 层次在哪个期间是低的期间发现了一个特定的时期(E8.5-9.5 ) 。随后, 5hmC 层次增加在 E11.5 到达它的山峰并且逐渐地由复制依赖者冲淡多半减少直到 E13.5。有趣地, 5hmC 在这个时期期间在 chromocenters 被充实。当时这个细菌房间特定的 5hmC subnuclear 本地化模式甚至在成熟卵母细胞在女细菌房间被维持,当有丝分裂的增长在新生的阶段期间恢复,如此的模式逐渐地在男细菌房间被失去。Pericentric 5hmC 在 silencing 起一个重要作用主要卫星重复,特别在女 PGC。由 RNA-seq 的全球 transcriptome 分析表明差别的大多数从 E9.5 表示了基因到 13.5 是在男、女的 PGC 的 upregulated。尽管仅仅女 PGC 在出生前的阶段期间进入成熟分裂,成熟分裂相关并且印的基因的一个子集是显著地在在 E13.5 的男、女的 PGC 的 upregulated。因此,我们的学习不仅在 PGC reprogramming 和细菌房间期间揭示 5mC 和 5hmC 的动力学开发,而且他们在 epigenetic reprogramming 和 meiotic 和印的基因的 transcriptional 规定的潜在的角色。 | Shinpei Yamaguchi Kwonho Hong Rui Liu Azusa Inoue Li Shen Kun Zhang Yi Zhang | 2013 | Cell Research2013，23，3： | 10 |
| 15 | Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer显示文摘 | Yuji Maehata Shotaro Nakamura Kiyoshi Fujisawa Motohiro Esaki Tomohiko Moriyama Kouichi Asano Yuta Fuyuno Kan Yamaguchi Issei Egashira Hyonji Kim Motonobu Kanda Minako Hirahashi Takayuki Matsumoto | 2012 | Gastrointestinal Endoscopy2012，，1： | 10 |
| 16 | A New Phenylpropanol Glycoside and Its Five Known Analogues from Boschniakia rossica显示文摘Objective To study the constituents in the whole plant of Boschniakia rossica. Methods The constituents were separated and purified with chromatographic methods. Their structures were elucidated by spectroscopic methods (1D, 2D NMR, UV, IR, and HRESI-TOF-MS) and chemical analyses. Results One new phenylpropanol glycoside (1) and its five known analogues were obtained from B. rossica. They were identified as trans-p-coumaryl- (2′-O-β-D-glucopyranosyl)-β-D-glucopyranoside (1), salidroside I (2), rossicasin A (3), trans-p-coumaryl alcohol 1-O-β-glucopyranosyl(1→4)-α-rhamnopyranosyl(1→3)-β-glucopyranoside (4), salidroside (5), and acetoside (6). Conclusion Among the known compounds, compound 2 is firstly isolated from the plants in genus Boschniakia C. A. Mey. ex Bongard. Meanwhile, the 13 C-NMR data of 9 and 4′ positions in compound 4 are corrected. | WU Chun-hua WANG Tao YAMAGUCHI Yoshihiro CHEN Yue HAN Li-feng ZHANG Yi | 2013 | Chinese Herbal Medicines2013，5，1： | 10 |
| 17 | Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis显示文摘A 72-year-old woman with a sigmoid colon cancer and a synchronous colorectal liver metastasis(CRLM),which involved the right hepatic vein(RHV)and the inferior vena cava(IVC),was referred to our hospital.The metastatic lesion was diagnosed as initially unresectable because of its invasion into the confluence of the RHV and IVC.After she had undergone laparoscopic sigmoidectomy for the original tumor,she consequently had 3 courses of modified 5-fluorouracil,leucovorin,and oxaliplatin(m FOLFOX6)plus cetuximab.Computed tomography revealed a partial response,and the confluence of the RHV and IVC got free from cancer invasion.After 3 additional courses of m FOLFOX6 plus cetuximab,preoperative percutaneous transhepatic portal vein embolization(PTPE)was performed to secure the future remnant liver volume.Finally,a right hemihepatectomy was performed.The postoperative course was uneventful.The patient was discharged from the hospital on postoperative day 13.She had neither local recurrence nor distant metastasis 18 mo after the last surgical intervention.This multidisciplinary strategy,consisting of conversion chemotherapy using FOLFOX plus cetuximab and PTPE,could contribute in facilitating curative hepatic resection for initially unresectable CRLM. | Kenta Baba Akihiko Oshita Mohei Kohyama Satoshi Inoue Yuta Kuroo Takuro Yamaguchi Hiroyuki Nakamura Yoichi Sugiyama Tatsuya Tazaki Masaru Sasaki Yuji Imamura Yutaka Daimaru Hideki Ohdan Atsushi Nakamitsu | 2015 | World Journal of Gastroenterology2015，21，6： | 10 |
| 18 | S-1 in the treatment of pancreatic cancer显示文摘S-1 is an oral 5-fluorouracil(5-FU) prodrug,which is designed to improve the antitumor activity of 5-FU by inhibiting dihydropyrimidine dehydrogenase,the key enzyme of 5-FU catabolism.Recently,two important studies on the clinical use of S-1 for pancreatic cancer have been reported from Japan.In the first study(GEST study),S-1 demonstrated non-inferiority to gemcitabine(GEM) in overall survival(OS) for metastatic or locally advanced pancreatic cancer,but combination chemotherapy with GEM and S-1 did not show superiority to GEM in OS.In the second study(JASPAC-01 study),S-1 showed superiority to adjuvant chemotherapy with GEM in OS in patients with resected pancreatic cancer.In addition to GEM,S-1 is now regarded as the key drug in the management of pancreatic cancer in Japan.To date,many studies have investigated the effectiveness of S-1 in various settings,such as first-line chemotherapy for metastatic or locally advanced pancreatic cancer,second-line chemotherapy after GEM failure,and chemoradiotherapy for locally advanced disease.In this review,we focus on recent clinical trials of S-1-based chemotherapy for advanced pancreatic cancer. | Kentaro Sudo Kazuyoshi Nakamura Taketo Yamaguchi | 2014 | World Journal of Gastroenterology2014，20，41： | 9 |
| 19 | Long-term outcomes and prognostic factors of patients with obstructive colorectal cancer: A multicenter retrospective cohort study显示文摘AIM: To investigate the long-term oncologic outcomes and prognostic factors in patients with obstructive colorectal cancer(CRC) at multiple Japanese institutions.METHODS: We identified 362 patients diagnosed with obstructive colorectal cancer from January 1, 2002 to December 31, 2012 in Yokohama Clinical Oncology Group's department of gastroenterological surgery. Among them, 234 patients with stage Ⅱ/Ⅲ disease who had undergone surgical resection of their primary lesions were analyzed, retrospectively. We report the long-term outcomes, the risk factors for recurrence, and the prognostic factors.RESULTS: The five-year disease free survival and cancer-specific survival were 50.6% and 80.3%, respectively. A multivariate analysis showed the ASAPS(HR = 2.23, P = 0.026), serum Albumin ≤ 4.0 g/d L(HR = 2.96, P = 0.007), T4 tumor(HR = 2.73, P = 0.002) and R1 resection(HR = 6.56, P = 0.02) to be independent risk factors for recurrence. Furthermore, poorly differentiated cancers(HR = 6.28, P = 0.009), a T4 tumor(HR = 3.46, P = 0.011) and R1 resection(HR = 6.16, P = 0.006) were independent prognostic factors in patients with obstructive CRC.CONCLUSION: The outcomes of patients with obstructive CRC was poor. T4 tumor and R1 resection were found to be independent prognostic factors for both recurrence and survival in patients with obstructive CRC. | Ishibe Atsushi Ota Mitsuyoshi Yamaguchi Kazuya Kaida Syuhei Kamiya Noriyuki Momiyama Masashi Watanabe Akira Sekizawa Kentaro Kamimukai Nobuyuki Sugimasa Natsuko Watanabe Jun Ichikawa Yasushi Kunisaki Chikara Endo Itaru | 2016 | World Journal of Gastroenterology2016，22，22： | 9 |
| 20 | Clinical significance of serum levels of vascular endothelial growth factor and its receptor in biliary disease and carcinoma显示文摘AIM: To investigate the clinical significance of serum vascular endothelial growth factor (VEGF) and soluble VEGF receptor-1 (VEGFR1/Flt-1) (sVEGFR1) levels in biliary diseases.METHODS: We analyzed the serum levels of these proteins in patients with acute cholangitis (group 1), biliary malignancies (group 2), and primary biliary cirrhosis or primary sclerosing cholangitis (group 3), and in healthy donors (group 4). The influence of inflammation was also analyzed. Serum VEGF levels were expressed as VEGF per platelet (VEGF/PLT, pg/106) in order to exclude the influence of platelet counts.RESULTS: sVEGFR1 levels were significantly higher in groups 1 and 2 than in the control group, but did not correlate with inflammatory markers. VEGF/PLT levels were generally higher in patients with active inflammation than in those with carcinoma. C-reactive protein strongly correlated with the levels of serum VEGF independently of platelet and leukocyte counts, even in cancer patients. In cancer patients, VEGF/PLT and sVEGFR1 levels might be indicators for evaluating the effect of medical treatment or the disease progression.CONCLUSION: Serum VEGF and VEGFR1 might be useful markers for gauging the clinical effect of various treatments on patients. | Munechika Enjoji Makoto Nakamuta Koji Yamaguchi Satoshi Ohta Kazuhiro Kotoh Marie Fukushima Masami Kuniyoshi Tomomi Yamada Masao Tanaka Hajime Nawata | 2005 | World Journal of Gastroenterology2005，11，8： | 9 |
您所在的机构暂未开通此部分的功能，请联系管理员